Open-Label Study of Oral Treprostinil in Digital Ulcers

PHASE2TerminatedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Systemic Sclerosis
Interventions
DRUG

treprostinil diethanolamine

sustained release tablet; BID dosing; up to 16 mg BID

Trial Locations (26)

10021

The Hospital for Special Surgery, New York

11042

North Shore - LIJ Health System, Lake Success

15261

University of Pittsburgh, Pittsburgh

20007

Georgetown University - Dept. of Medicine/Rheumatology, Washington D.C.

21224

Johns Hopkins University - Division of Rheumatology, Baltimore

43614

University of Toledo, Toledo

44195

The Cleveland Clinic Foundation, Cleveland

48106

University of Michigan - Scleroderma Program, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60611

Northwestern University - Feinberg School of Medicine, Chicago

77030

University of Texas - Houston, Houston

80045

Barbara Davis Centre, Aurora

84132

University of Utah, Salt Lake City

85259

Mayo Clinic Scottsdale, Scottsdale

98101

Virginia Mason Medical, Seattle

35294-7201

University of Alabama - Birmingham - Arthritis Clinical Intervention Program, Birmingham

90095-1670

UCLA, Los Angeles

06030-1310

University of Connecticut Health Center, Farmington

02118-2526

Boston University School of Medicine, Boston

08903

UMDNJ Clinical Research Center, New Brunswick

29425-8900

Medical University of South Carolina, Charleston

N6A 4V2

St Joseph's Health Care, London

H3T 1E2

Jewish General Hospital, Montreal

NW3 2QG

Royal Free Hospital - Center for Rheumatology, London

M13 9PT

Salford Royal Hospital, Manchester

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY